NeuroPace, Inc.

NASDAQ:NPCE

Medical - Devices

Healthcare
$8.22 +0.30%

+$0.05 today

Market cap
$283.19M
Beta
1.88
P/E (TTM)
-23.8
EPS (TTM)
-$0.64
52W Low $7.56High $19.60

Volume 0.31M

Average 0.18M

NPCE Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

NeuroPace, Inc.NASDAQ: NPCE

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue dips below year-ago levels

Q1 FY2026 cost of revenue of $4.02M fell 22.4% year over year, behind the +1.8% change in trailing-twelve-month cost of revenue. Sequentially, it fell 33.1% from the prior quarter. Over 3 fiscal years it compounded at +20.5% a year.

Context

  • Cost of revenue amounted to 22.8% of revenue in FY2025, down 3.3 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -22.4% toward the trailing-twelve-month pace of +1.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.02M-33.1% QoQ
Last fiscal yearDec 2025
$22.77M+9.3% YoY
LTMMar 2026
$21.6M+1.8% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-22.4%——
1 year+9.3%——
3-year CAGR+20.5%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
22.77M USD
Year-over-year change
+9.3%
4-year CAGR
+18.0%

Cost of Revenue vs competitors

How NPCE compares with its peers on the latest reported figures

  • NPCE's LTM Mar 2026 cost of revenue of $21.6M is the highest of the 2 companies compared; the peer median is $8.55M.
  • Its year-over-year change of +1.8% is the highest of 2, against a peer median of -0.9%.
  • Cost of revenue amounts to 21.7% of revenue for NPCE, versus a peer median of 14.5%.
NPCE Competitors Peer median
Cost of Revenue for NPCE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NPCENeuroPace, Inc.LTM Mar 2026$21.6M +1.8%+20.5%21.7%
CVRXCVRx, Inc.LTM Mar 2026$8.55M -0.9%+18.5%14.5%
MOBIMobia Medical, Inc. Common Stock—— ———
Peer median (excluding NPCE) $8.55M-0.9%+18.5%14.5%

Competitors are the stored peer set for NPCE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue45.18M45.52M65.42M79.91M99.99M
Cost of Revenue11.75M13.03M17.3M20.82M22.77M
Gross Profit33.44M32.49M48.12M59.09M77.22M
Gross Margin74.0%71.4%73.6%73.9%77.2%
Research & Development18.21M21.95M20.78M23.65M27.89M
Selling, General & Admin38.96M51.34M54.52M57.1M65.67M
Operating Expenses57.17M73.29M75.3M80.76M93.56M
Depreciation & Amortization296K2.99M1.61M1.77M1.95M
EBITDA(28.37M)(36.57M)(22.83M)(16.57M)(12.06M)
EBITDA Margin-62.8%-80.3%-34.9%-20.7%-12.1%
Operating Income(23.74M)(40.79M)(27.17M)(21.67M)(16.34M)
Operating Margin-52.5%-89.6%-41.5%-27.1%-16.3%
Interest Income448K1.58M3.05M3.02M2.82M
Interest Expense7.41M7.53M8.52M8.8M7.46M
Other Income / Expenses(12.34M)(6.29M)(5.78M)(5.47M)(5.13M)
Income Before Tax(36.08M)(47.08M)(32.96M)(27.14M)(21.47M)
Pre-Tax Margin-79.9%-103.4%-50.4%-34.0%-21.5%
Income Tax Expense00000
Net Income(36.08M)(47.08M)(32.96M)(27.14M)(21.47M)
Net Margin-79.9%-103.4%-50.4%-34.0%-21.5%
EPS (Basic)(2.17)(1.91)(1.27)(0.93)(0.66)
EPS (Diluted)(2.17)(1.91)(1.27)(0.93)(0.66)
Weighted Avg Shares16.61M24.59M25.85M29.13M32.72M
Weighted Avg Shares (Diluted)16.61M24.59M25.85M29.13M32.72M

NeuroPace, Inc.

NASDAQ:NPCE

Intrinsic Alpha fair value

Locked

Current Price

$8.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.